Brief: Epigenomics enters agreement with Biochain on lung cancer test for China
30/03/2016 08:02
March 30 (Reuters) - Epigenomics AG ECXn.DE :
* Enters strategic license and development agreement with
Biochain on novel, blood-based lung cancer test for China
* Will receive undisclosed upfront, milestone and minimum
annual payments as well as mid single-digit royalty on future
revenues
* Biochain will initiate a clinical trial to validate lung
cancer detection test with goal to gain market approval by CFDA
* Trial is expected to start in 2016
Source text for Eikon: ID:nEQ3RdlT4a
Further company coverage: ECXn.DE
(Gdynia Newsroom)
((gdynia.newsroom@thomsonreuters.com; +48 58 698 3920;))
Recent news on Epigenomics AG
See all newsU.S. FDA advisers back approval for Guardant's blood-based cancer test (updated)
U.S. FDA advisers back approval for Guardant's cancer test
Brief: Epigenomics Says Closing Of Agreement On The Acquisition Of Almost All Assets And Adjustment Of Guidance For 2023
Brief: Epigenomics AG Says It Entered Into Agreement On The Acquisition Of Almost All Assets With New Day Diagnostics LLC
Brief: Epigenomics Says Chief Scientific Officer Andrew Lukowiak Resigns